Innate Pharma SA (NAS:IPHA)
$ 1.9 0.05 (2.7%) Market Cap: 153.81 Mil Enterprise Value: 93.89 Mil PE Ratio: 0 PB Ratio: 4.75 GF Score: 56/100

Q4 2021 Innate Pharma SA Earnings Call Transcript

Mar 24, 2022 / 01:00PM GMT
Release Date Price: $3.36 (-3.17%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Innate Pharma Full Year 2021 Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I will now hand over to Mr. Henry Wheeler, Head of Investor Relations of Innate Pharma, to begin. Sir, please go ahead.

Henry Wheeler
Innate Pharma S.A. - VP & Head of IR

Thank you. Good morning, good afternoon, and welcome, everyone.

This morning, Innate issued a press release providing a business update for the 2021 full year results. We look forward to presenting the progress made during the year to date as well as addressing future goals and (inaudible) .

The press release and today's presentation are both available on the IR section of the website.

On Slide 2, I would like to remind you that we will make forward-looking statements regarding the financial outlook, in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot